Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 3/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.40 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7110432 | 0.88 | L3MBTL1 (0.60) | L3MBTL1MAPTLMNASMN1; SMN2CTSV | |
| SCHEMBL5197720 | 0.81 | L3MBTL1 (0.59) | L3MBTL1MAPTLMNASMN1; SMN2CTSV | |
| SCHEMBL7251510 | 0.80 | PPARG (0.53) | KIF11 | |
| SCHEMBL7106197 | 0.79 | L3MBTL1 (0.53) | L3MBTL1MAPTLMNASMN1; SMN2CTSV | |
| SCHEMBL5195006 | 0.79 | L3MBTL1 (0.57) | L3MBTL1MAPTLMNASMN1; SMN2CTSV | |
| SCHEMBL5193224 | 0.78 | L3MBTL1 (0.56) | L3MBTL1MAPTLMNASMN1; SMN2CTSV | |
| SCHEMBL7967629 | 0.78 | MAPT (0.55) | L3MBTL1MAPTLMNASMN1; SMN2TRPM8 | |
| SCHEMBL3811564 | 0.74 | L3MBTL1 (0.80) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL4843195 | 0.74 | L3MBTL1 (0.61) | L3MBTL1MAPTLMNASMN1; SMN2HTT | |
| SCHEMBL18264073 | 0.73 | L3MBTL1 (0.55) | L3MBTL1MAPTLMNASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | ASAHI-KASEI KABUSHIKI KAISHA (JP) | 2003-02-27 | — | — | US | disclosed |
| EP-1238973-A1 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | CPT1A, CBR1, NR1H3 | L3MBTL1 518/4885MAPT 4835/4885LMNA 3664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.